RTP Mobile Logo
What General Medical Oncologists Want to Know About Immunotherapy and Other Nontargeted Approaches for Lung Cancer (Webinar Audio Proceedings)
Released September 2021

Featuring perspectives from Drs Mark Awad, David R Spigel and Heather Wakelee. Published September 8, 2021. (Webinar Audio Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

    LEARNING OBJECTIVES

    • Appraise data leading to the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and appropriately integrate this strategy into routine clinical practice.
    • Acknowledge available Phase III findings supporting the recent FDA approval of cemiplimab as first-line therapy for PD-L1-positive NSCLC without EGFR, ALK or ROS1 aberrations, either locally advanced in patients not eligible for surgical resection or definitive chemoradiation or in those with metastatic disease.
    • Recognize the FDA approvals of nivolumab in combination with ipilimumab with and without chemotherapy as first-line therapy for metastatic NSCLC, and appropriately incorporate these novel regimens into treatment algorithms.
    • Discuss ongoing trials and recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for metastatic NSCLC, and discern how these approaches can be optimally employed in disease management.
    • Appreciate available clinical trial findings informing the use of immune checkpoint inhibitors in combination with platinum-based chemotherapy for patients with previously untreated extensive-stage small cell lung cancer (SCLC).
    • Consider the FDA approval of lurbinectedin for patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy, and discern how this agent can be optimally employed in nonresearch therapy.
    • Design an optimal approach to the clinical care of patients with progressive SCLC, considering the implications of prior therapeutic exposure, symptomatology and other factors.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOLungImmuno21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASCOLungImmuno21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOLungImmuno21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASCOLungImmuno21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Mark Awad, MD, PhD
    Clinical Director, Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: ArcherDX, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Maverick Therapeutics, Merck, Mirati Therapeutics, Nektar, NextCure, Novartis, Syndax Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly; Data and Safety Monitoring Board/Committee: Apollomics Inc, Bristol-Myers Squibb Company.

    David R Spigel, MD
    Chief Scientific Officer
    Thoracic Oncology
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements (to Institution): Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Curio Biotech SA, Dracen Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Iksuda Therapeutics, Illumina, Intellisphere LLC, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Merck, Mirati Therapeutics, Molecular Templates, Nektar, Novartis, Novocure, Pfizer Inc, PharmaMar, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Takeda Oncology, Triptych Health Partners, TRM Oncology; Contracted Research (to Institution): Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Apollomics Inc, Astellas, AstraZeneca Pharmaceuticals LP, BIND Therapeutics Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, EMD Serono Inc, G1 Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Grail Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Molecular Partners, Nektar, Neon Therapeutics, Novartis, Novocure Inc, Takeda Oncology, Tesaro, A GSK Company, Transgene, University of Texas.

    Heather Wakelee, MD
    Professor of Medicine
    Chief, Division of Oncology
    Stanford University School of Medicine
    Deputy Director, Stanford Cancer Institute
    Stanford, California

    Advisory Board (Compensated): AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Helsinn Healthcare SA, Janssen Biotech Inc, Mirati Therapeutics, Xcovery; Advisory Board (Not Compensated): Cellworks, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Research Funding to Institution: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics,AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Xcovery.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc and Turning Point Therapeutics Inc.

    Release date: September 2021
    Expiration date: September 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to program
(WIFI is recommended for best performance):